Pune: The Maharashtra Food and Drug Administration (FDA) has cancelled the wholesale drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd’s carrying and forwarding (C&F) warehouse at Wadki in Pune, citing alleged regulatory and storage-related irregularities.
During an inspection, officials allegedly found stocks of Reactin Plus Tablets, a Schedule H drug. “Cipla maintains an unwavering commitment to quality and patient safety, and we find the Maharashtra FDA’s decision regarding our Wadki C&FA in Pune disappointing. We believe our Pune C&FA warehouse operates in compliance with distribution and storage protocols and digital record-keeping standards.
The authority said the packaging described the medicine as an “Analgesic & Anti-inflammatory” and made claims of quick relief from headaches, muscular pain, backache, joint pain, sprain-related pain, body aches and toothaches. We are reviewing the order and evaluating further options,” the company said.
